Metformin and breast and gynecological cancer risk among women with diabetes

Diana Soffer,¹ Jiaxiao Shi,¹ Joanie Chung,¹ Joanne E Schottinger,¹ Lauren P Wallner,¹ Rowan T Chlebowski,² Scott E Lentz,³ Reina Haque¹

ABSTRACT
Objective: We investigated if metformin lowers breast, endometrial, and ovarian cancer risk in women with type 2 diabetes mellitus compared with women who used other antidiabetic medications.

Research design and methods: We followed a cohort of 66 778 female patients with diabetes for a maximum of 12 years (median 6 years). We examined breast, endometrial, and ovarian cancer risk, and the composite cancer risk. We examined drug categories using pharmacy records: metformin only; metformin combination regimens; non-metformin regimens; and non-users. We used χ² analyses to examine categorical variables. We conducted multivariable Cox regression models with time-dependent drug use status.

Results: Women who used metformin combination regimens versus metformin only had a 15% lower breast cancer risk (adjusted HR=0.85, 95% CI 0.69 to 1.04). After stratifying by glycated hemoglobin (HbA1c), the association attenuated in those who had poorly controlled HbA1c (adjusted HR=1.06, 95% CI 0.73 to 1.55). Given the small numbers of ovarian and endometrial cancer outcomes, we examined these as a composite. The risk of all cancers combined was similar in those who used metformin combination regimens versus metformin only (adjusted HR=0.92, 95% CI 0.78 to 1.10). We found no significant differences for breast cancer or all cancers combined when we compared risks in non-metformin users versus metformin only users.

Conclusions: Women who used metformin and other antidiabetic drugs had a lower breast cancer risk compared with women who used metformin only, but the results were not significant. We also found no difference in overall cancer risks when we compared women who used other antidiabetic drugs (no metformin) versus metformin users.

INTRODUCTION
Epidemiological studies suggest that hyperinsulinemia, insulin resistance, and diabetes are associated with increased cancer risks.¹⁻³ Metformin improves glycemic control and is used to treat type 2 diabetes, and based on in vitro studies, the drug may have anticancer effects,⁴⁻⁷ particularly for breast cancer.⁸

Key messages
- We conducted a study that used comprehensive pharmacy longitudinal records from an integrated healthcare delivery system of nearly 67 000 female patients with type 2 diabetes who were followed for a maximum of 12 years, and exposed to various antidiabetic medications.
- Metformin alone was not associated with lower breast, endometrial, or ovarian cancer risks.
- Overall, our results do not support the beneficial role of metformin monotherapy in lowering the risk of developing breast or gynecological cancer.

While several studies described a lower cancer risk among patients with type 2 diabetes using metformin, other studies have disputed metformin’s protective effect.⁹⁻¹⁶ One case–control study of 11 000 women with type 2 diabetes in Scotland showed that overall cancer incidence was lower in patients taking metformin, and also suggested that there was a dose–response relationship.² This study was later expanded into a cohort study to confirm this overall reduction and found a lower incidence of all cancers from 11% to 8% as well as lower overall and cancer-related mortality in metformin users. Another prospective study of 1353 patients in the Netherlands similarly demonstrated lower cancer mortality among those with type 2 diabetes using metformin compared with non-users.¹⁷ These observations have also been generally found when analyzing the impact of metformin use on specific cancers. A case–control analysis of 22 621 women with type 2 diabetes found an adjusted OR of 0.44 for developing breast cancer in those on long-term metformin treatment when compared to women with diabetes not using metformin.¹⁸ In contrast, other studies have found no association with metformin,¹¹⁻¹⁶ while one found an increased risk of various cancers among metformin users.¹⁹ However, prior studies were limited by self-reported...
Epidemiology/Health Services Research

medication use data, short follow-up duration, inclusion of patients without diabetes, or limited covariate data. With little data available on metformin use in gynecological cancers, our goal was to examine whether metformin use had an impact on breast, endometrial, or ovarian cancer incidence in a large cohort of adult women with type 2 diabetes with pharmacy and healthcare coverage.

RESEARCH DESIGN AND METHODS

Design, setting, and study population
We assembled a large cohort of female patients with type 2 diabetes using the membership of Kaiser Permanente Southern California (KPSC), a large not-for-profit integrated healthcare delivery system that serves over 3.3 million members in the region. All data elements were extracted from the KPSC comprehensive electronic health records. Potential subjects were patients with newly diagnosed diabetes from 1998 to 2004 as identified from the health plan’s diabetes registry (N=232 637 with peak glycated hemoglobin (HbA1c)>7.5%; 58 mmol/mol). This group included new users of antidiabetic medications (those exposed to diabetic medications prior to study entry date were ineligible) and patients not treated with any antidiabetic medications. We also excluded males, those who were <18 years of age, and who were enrolled for less than 1 year in the health plan during the study, and who had a history of cancer prior to the diabetes diagnosis date (N=165 805). The final cohort consisted of 66 778 adult women with diabetes.

Outcomes and follow-up
The cohort was followed (using electronic health records) from the time of diabetes diagnosis (study entry date) to one of four end points, whichever occurred first: (1) diagnosis of breast, endometrial, or ovarian cancer, (2) disenrollment from the health plan, (3) study’s end (December 31, 2009) or (4) patient death. Thus, the maximum follow-up was 12 years post-first study event. The peak HbA1c level ascertained during the follow-up period was defined as the worst HbA1c level during theigic health regard to both the antidiabetic user or non-user categorization, the incidence of patients with diabetes, and healthcare coverage.

Pharmacy records: antidiabetic medications
Antidiabetic medications (type, prescription dates, days supplied) were captured from the KPSC pharmacy records. Initially, women were classified into mutually exclusive groups based on their overall pattern of drug use over the study period (table 1): (1) single-agent metformin users (“metformin only”); (2) combination users (used metformin concurrently or sequentially with sulfonylureas, insulin, and ‘other’ hypoglycemic agents, which were less frequently prescribed, such as α-glucosidase inhibitors, incretin mimetics, amylinomimetics, meglitinides, dipeptidyl peptidase-4 inhibitors, incretin mimetics, insulin, meglitinides, sulfonylureas; thiazolidinediones (glitazones).

| Table 1 Distribution of antidiabetic medication use in a cohort of 66 778 women with type 2 diabetes |
|-------------------------------------------|
| **Antidiabetic medication** | **N** | **Per cent** |
|-----------------------------|--------|--------------|
| Metformin only              | 4887   | 7.32         |
| Metformin combinations      |        |              |
| Metformin+sulfonylureas only| 11 193 | 16.76        |
| Metformin-insulin only      | 655    | 0.98         |
| Metformin-other non-metformin drugs* | 10 189 | 15.26       |
| Non-metformin               |        |              |
| Sulfonylureas only          | 8253   | 12.36        |
| Insulin only                | 4705   | 7.05         |
| Other non-metformin drugs*  | 1907   | 2.86         |
| Non-antidiabetic medication users | 24 989 | 37.42       |
| Total                       | 66 778 |              |

*Exposed to one or more of these classes: α-glucosidase inhibitors; amylinomimetics; biguanides; dipeptidyl peptidase-4 inhibitors; incretin mimetics; insulin; meglitinides; sulfonylureas; thiazolidinediones (glitazones).

Covariates
Baseline covariates for which each patient was evaluated included: age at baseline (entry into cohort), race/ethnicity, geocoded income categories, prior use of estrogen replacement therapy (ERT), ever statin use, Charlson comorbidity index (1 year prior to entry into cohort), and number of outpatient visits during study period. The peak HbA1c level ascertained during follow-up was used as a surrogate marker for diabetes severity, and stratified into three groups (<7% (53 mmol/mol), 7–9.4% (53–80 mmol/mol), and ≥9.5% (80 mmol/mol)). Since multiple HbA1c levels were found per patient, we used the peak value to determine the level of control.
|                                | Metformin users | Combination users | Non-metformin users | Non-antidiabetic users | Total |
|--------------------------------|-----------------|-------------------|--------------------|------------------------|-------|
|                                | N               | %                 | N                  | %                       | N     |
| Total women                     | 4887            | 7.32              | 22 037             | 33.00                  | 14 865| 22.26 | 24 989 | 37.42 | 66 778| 100   |
| Age at index DM date            |                 |                   |                    |                         |       |
| <30                             | 120             | 2.46              | 689                | 3.13                   | 1592  | 10.71 | 1576   | 6.31  | 3977  | 5.96  |
| 30–39                           | 349             | 7.14              | 2375               | 10.78                  | 3172  | 21.34 | 3006   | 12.03 | 8902  | 13.33 |
| 40–49                           | 934             | 19.11             | 5652               | 25.65                  | 1995  | 13.42 | 3336   | 13.35 | 11 917| 17.85 |
| 50–59                           | 1589            | 32.51             | 7168               | 32.53                  | 2485  | 16.72 | 4329   | 17.32 | 15 571| 23.32 |
| 60–69                           | 1287            | 26.34             | 4228               | 19.19                  | 2557  | 17.20 | 4729   | 18.92 | 12 801| 19.17 |
| 70–79                           | 535             | 10.95             | 1671               | 7.58                   | 2086  | 14.03 | 4792   | 19.18 | 9084  | 13.60 |
| 80+                             | 73              | 1.49              | 254                | 1.15                   | 978   | 6.58  | 3221   | 12.89 | 4526  | 6.78  |
| p Value*                        | <0.0001         |                   |                    |                         |       |
| Mean±SD                         | 56.2±12.1       | 53.1±12.1         | 52.7±18.0          | 59.1±18.0              | 55.5±16.1|       |
| Race/ethnicity                  |                 |                   |                    |                         |       |
| Non-Hispanic caucasians         | 1592            | 32.58             | 7054               | 32.01                  | 4988  | 33.56 | 10 746 | 43.00 | 24 380| 36.51 |
| Hispanic                        | 1321            | 27.03             | 6975               | 31.65                  | 4662  | 31.36 | 6145   | 24.59 | 19 103| 28.61 |
| African American                | 568             | 11.62             | 3267               | 14.83                  | 2022  | 13.60 | 3192   | 12.77 | 9049  | 13.55 |
| Asian/PIs                       | 500             | 10.23             | 1875               | 8.51                   | 1390  | 9.35  | 1621   | 6.49  | 5386  | 8.07  |
| Others/unknown                  | 906             | 18.54             | 2866               | 13.01                  | 1803  | 12.13 | 3285   | 13.15 | 8860  | 13.27 |
| p Value*                        | <0.0001         |                   |                    |                         |       |
| Geocoded income                 |                 |                   |                    |                         |       |
| Lower 25% (≤US$43 022)          | 1100            | 22.51             | 5508               | 24.99                  | 3935  | 26.47 | 5920   | 23.69 | 16 463| 24.65 |
| >25–50% (≥US$43 023–US$58 415)  | 1224            | 25.05             | 5420               | 24.59                  | 3677  | 24.74 | 6141   | 24.57 | 16 462| 24.65 |
| >50–75% (≥US$58 416–US$77 536)  | 1181            | 24.17             | 5631               | 25.55                  | 3597  | 24.20 | 6054   | 24.23 | 16 463| 24.65 |
| Top 25% (≥US$77 537)            | 1320            | 27.01             | 5242               | 23.79                  | 3429  | 23.07 | 6468   | 25.88 | 16 459| 24.65 |
| Unknown/missing                 | 62              | 1.27              | 236                | 1.07                   | 227   | 1.53  | 406    | 1.62  | 931   | 1.39  |
| p Value*                        | <0.0001         |                   |                    |                         |       |
| Estrogen replacement treatment  |                 |                   |                    |                         |       |
| during study period             |                 |                   |                    |                         |       |
| Yes                             | 1359            | 27.81             | 7301               | 33.13                  | 3050  | 20.52 | 6019   | 24.09 | 17 729| 26.55 |
| No                              | 3528            | 72.19             | 14 736             | 66.87                  | 11 815| 79.48 | 18 970 | 75.91 | 49 049| 73.45 |
| p Value*                        | <0.0001         |                   |                    |                         |       |
| Parity (live births)            |                 |                   |                    |                         |       |
| 0                               | 58              | 1.19              | 409                | 1.86                   | 941   | 6.33  | 726    | 2.91  | 2134  | 3.20  |
| 1–2                             | 128             | 2.62              | 985                | 4.47                   | 2443  | 16.43 | 2032   | 8.13  | 5588  | 8.37  |
| 3–4                             | 31              | 0.63              | 329                | 1.49                   | 611   | 4.11  | 535    | 2.14  | 1506  | 2.26  |
| 5+                              | 5               | 0.10              | 47                 | 0.21                   | 92    | 0.62  | 66     | 0.26  | 210   | 0.31  |
| Missing                         | 4665            | 95.46             | 20 267             | 91.97                  | 10 778| 72.51 | 21 630 | 86.56 | 57 340| 85.87 |
| p Value*                        | <0.0001         |                   |                    |                         |       |
We compared the covariate distributions by antidiabetic drug use status using contingency tables and χ² analysis. Rates of cancer incidence (per 1000 woman-years) were also estimated (table 2). Overall and adjusted HRs were estimated using multivariate Cox regression analysis (table 2) for the subset of patients who used antidiabetic medications to minimize confounding by indication, using the metformin only group as the reference group (ie, to examine the associations in the antidiabetic medication ‘user’ groups). In addition, separate Cox models were conducted for each cancer type, and also for all the three cancers combined. We further conducted sensitivity analyses by examining the HRs by level of HbA1c control. All analyses were performed using SAS V.9.1.

RESULTS
Overall, we identified 66 778 eligible women with type 2 diabetes for this study followed up to 12 years post-study entry. Of these 66 778 women, 41 789 who used antidiabetic medications were followed for a median of 6.5 years (range 0–12 years; interquartile 3.9–8.8 years). The non-user group (N=24 989) was followed for a median of 5.2 years (range 0–12 years; IQR 1.7–7.4 years). Table 1 shows the distribution of the cohort based on the patients’ final combination of exposure to antidiabetic drugs in mutually exclusive categories. Among patients who used antidiabetic medications, 4887 (7.3%) were single-agent metformin users, 11 193 (16.8%) used metformin with sulfonylureas, 655 (0.9%) used metformin with insulin, 10 189 (15.3%) used metformin with other hypoglycemic medications, 8253 (12.4%) used sulfonylureas only, 4705 (7.1%) used insulin only, 1907 (2.9%) used other hypoglycemic medications only, and 24 989 (37.4%) did not use any antidiabetic medication (table 1). Since our primary objective was to examine the independent and combined effects of metformin use, we further categorized the aforementioned groups as follows: metformin only (n=4887); combination users (used metformin with other antidiabetic medications concurrently or sequentially, n=22 037); non-metformin users (n=14 865); and non-antidiabetic medication users (‘non-users’, n=24 989; table 1).
In terms of parity, women who were non-metformin users were more likely to have had one to two pregnancies. Non-users were more likely to have a higher comorbidity index ($p<0.0001$). The distribution of geocoded income levels did not vary substantially with medication categories. In examining the Charlson comorbidity index, women who used metformin (with or without other antidiabetic medications) were less likely to have a comorbidity than non-metformin users or non-users. As expected, outpatient utilization was somewhat lower in women who were not treated with diabetic medications.

Of the 66,778 cohort members, 1572 developed breast cancer; 348 developed endometrial cancer; and 163 developed ovarian cancer; 7826 died; 22,943 disenrolled from the health plan; and 33,926 reached the study’s end. Median follow-up was 6 years (range of 0–12 years) for the overall cohort. The median age at cancer diagnosis was 55.3 years (range of 18–103 years).

Incidence rates for breast, endometrial, ovarian cancer, and all cancers combined are shown by mutually exclusive antidiabetic medication use categories in table 3. Cancer incidence rates varied by drug use categories, with non-metformin combination users having the greatest breast cancer rate (5.37/1000 person-years) followed by metformin only users (5.01/1000 person-years) as compared with non-users (3.95/1000 person-years). Breast cancer incidence rates were lowest among those who used sulfonylureas only (2.26/1000 person-years). Similarly, the endometrial cancer incidence rate was the highest among non-metformin combination users (1.32/1000 person-years) and metformin only users (1.32/1000 person years), and lowest among sulfonylurea users (0.24/1000 person-years). Given that there were only five cases of ovarian cancer in the metformin only group, inferences are not feasible. In all cancers combined, the pattern of cancer incidence rates was again similar to the pattern found for breast and endometrial cancer in the

| Cancer site          | Number of cases | Woman-years | Crude rate (per 1000) | 95% CI       |
|----------------------|-----------------|-------------|-----------------------|--------------|
| **Breast cancer**    |                 |             |                       |              |
| Metformin only       | 143             | 28,571      | 5.01                  | 4.22 to 5.90 |
| Metformin+sulfonylureas | 215         | 57,777      | 3.73                  | 3.25 to 4.27 |
| Metformin+insulin    | 6               | 2613        | 2.30                  | 0.84 to 5.00 |
| Metformin and other diabetic meds | 339 | 67,723      | 5.01                  | 4.49 to 5.57 |
| Sulfonylureas only   | 55              | 24,316      | 2.26                  | 1.70 to 2.94 |
| Insulin only         | 125             | 32,658      | 3.83                  | 3.19 to 4.56 |
| Other non-metformin drugs only | 46 | 8,560       | 5.37                  | 3.93 to 7.17 |
| Non-antidiabetic users | 643           | 162,820     | 3.95                  | 3.65 to 4.27 |
| **Endometrial cancer** |                |             |                       |              |
| Metformin only       | 36              | 28,571      | 1.26                  | 0.88 to 1.74 |
| Metformin+sulfonylureas | 60           | 57,777      | 1.04                  | 0.80 to 1.34 |
| Metformin+insulin    | 1               | 2613        | 0.38                  | 0.01 to 2.13 |
| Metformin and other diabetic meds | 71 | 67,723      | 1.05                  | 0.82 to 1.32 |
| Sulfonylureas only   | 6               | 24,316      | 0.25                  | 0.09 to 0.54 |
| Insulin only         | 33              | 32,658      | 1.01                  | 0.70 to 1.42 |
| Other non-metformin drugs only | 11 | 8,560       | 1.29                  | 0.64 to 2.30 |
| Non-antidiabetic users | 130           | 162,820     | 0.80                  | 0.67 to 0.95 |
| **Ovarian cancer**   |                 |             |                       |              |
| Metformin only       | 5               | 28,571      | 0.18                  | 0.06 to 0.41 |
| Metformin+sulfonylureas | 20           | 57,777      | 0.35                  | 0.21 to 0.54 |
| Metformin+insulin    | 0               | 2613        | 0.38                  | 0.01 to 2.13 |
| Metformin and other diabetic meds | 29 | 67,723      | 0.43                  | 0.29 to 0.61 |
| Sulfonylureas only   | 11              | 24,316      | 0.45                  | 0.23 to 0.81 |
| Insulin only         | 12              | 32,658      | 0.37                  | 0.19 to 0.64 |
| Other non-metformin drugs only | 7 | 8,560       | 0.82                  | 0.33 to 1.68 |
| Non-antidiabetic users | 79             | 162,820     | 0.49                  | 0.38 to 0.60 |
| **All cancers combined** |             |             |                       |              |
| Metformin only       | 184             | 28,571      | 6.44                  | 5.54 to 7.44 |
| Metformin+sulfonylureas | 295         | 57,777      | 5.12                  | 4.56 to 5.74 |
| Metformin+insulin    | 7               | 2613        | 2.68                  | 1.08 to 5.52 |
| Metformin and other diabetic meds | 439 | 67,723      | 6.48                  | 5.89 to 7.12 |
| Sulfonylureas only   | 72              | 24,316      | 2.96                  | 2.32 to 3.73 |
| Insulin only         | 170             | 32,658      | 5.21                  | 4.45 to 6.05 |
| Other non-metformin drugs only | 64 | 8,560       | 7.48                  | 5.76 to 9.55 |
| Non-antidiabetic users | 852           | 162,820     | 5.23                  | 4.89 to 5.60 |
metformin only group (6.44/1000 person-years) and non-user group (5.23/1000 person-years).

We further examined the association of breast cancer risk and all cancer risk (given the larger number of events) in the antidiabetic drug user groups using time-dependent medication variables in separate Cox models (table 4). The drugs were categorized as combinations with metformin, combinations without metformin, and metformin only (reference group). The HRs were adjusted for age of index diabetes diagnosis, race/ethnicity, estrogen status, statin use, Charlson comorbidity index, and outpatient utilization. Among the user groups, combination users (with metformin) had a lower overall risk of breast cancer compared with metformin only users (adjusted HR=0.85, 95% CI 0.69 to 1.04), but the results were not significant. In the sensitivity analysis, we examined the risk stratified by the level of HbA1c control. Breast cancer risk was somewhat lower in those with better controlled HbA1c groups (<7% and 7–9.4% HbA1c), but not protective among those with higher HbA1c levels (≥9.5%; ≥80 mmol/mol; adjusted HR=1.06, 95% CI 0.73 to 1.55). However, CIs overlapped and crossed the null across all HbA1c categories. Similar patterns emerged for non-metformin combinations. Again, all CIs crossed the null, and are consistent with no associations. Regarding all cancers combined, we found no difference between combination users (either with or without metformin) versus metformin only users, even after stratifying by HbA1c.

**DISCUSSION**

Using comprehensive pharmacy longitudinal records of an integrated healthcare delivery system, in our cohort of nearly 67,000 female patients with type 2 diabetes who were followed for a maximum of 12 years and who were exposed to metformin and other antidiabetic drugs, our results do not support that metformin monotherapy was associated with lower breast cancer risk. Metformin only use was also not associated with a lower risk of endometrial or ovarian cancer, but this finding could have been due to the small numbers of women who developed these outcomes in the metformin only category. In general, compared with non-users of antidiabetic medications, those exposed to single therapies did not have lower cancer risks.

Our findings were generally consistent with studies that examined the antidiabetic drug categories with time-dependent analyses (ie, methods that we employed for the present study). In addition, we were able to account for drug switching and statin use. The existing literature on the protective role of metformin is unclear. For example, a few prior studies that accounted for time-related bias produced conflicting results for metformin, with some finding lower risks from metformin, and one finding an increased risk. Reasons for the conflicting findings include the short follow-up time; different study populations (some might have included healthier populations than others); or inability to account for changes in drug therapy over time.

Although in vitro and in vivo studies support metformin’s role in reducing cancer risks via AMP-activated protein kinase pathways to lower blood glucose and decreasing hepatic gluconeogenesis; inhibition of the mTOR pathway (involved in cell proliferation); stimulation of p53 tumor suppression; or affecting ki-67, which plays a role in tumor proliferation, our

---

**Table 4** HRs for cancer among women who used antidiabetic medications (using time-dependent variables), stratified by HbA1c

|                     | Overall | HbA1c <7.0% (≤53 mmol/mol) | HbA1c 7.0–9.4% (53–80 mmol/mol) | HbA1c ≥9.5% (≥80 mmol/mol) |
|---------------------|---------|---------------------------|--------------------------------|-----------------------------|
|                     | Adjusted | 95% CI                    | Adjusted                       | 95% CI                      | Adjusted                       | 95% CI                      | Adjusted                       | 95% CI                      |
| Breast cancer       | 0.85     | 0.69 to 1.04              | 0.96                           | 0.51 to 1.82                | 0.83                           | 0.62 to 1.11                | 1.06                           | 0.73 to 1.55                |
| Combination† vs metformin only | 0.89     | 0.74 to 1.09              | 0.87                           | 0.55 to 1.37                | 0.98                           | 0.75 to 1.30                | 0.84                           | 0.57 to 1.25                |
| Non-metformin drugs vs metformin only | 0.92     | 0.77 to 1.10              | 1.07                           | 0.61 to 1.88                | 0.85                           | 0.66 to 1.10                | 1.15                           | 0.83 to 1.60                |
| All cancers combined| 0.93     | 0.79 to 1.11              | 0.98                           | 0.65 to 1.48                | 1.00                           | 0.78 to 1.28                | 0.85                           | 0.60 to 1.20                |

*Adjusted for: age of index diabetes diagnosis, race/ethnicity, ERT status, statin use, Charlson comorbidity index, and outpatient utilization.
†Combination includes metformin use. ERT, estrogen replacement therapy; HbA1c, glycated hemoglobin.
study did not support these hypotheses. Our results suggest that taking a combination of antidiabetic drugs generally lowered cancer risk overall, although the results did not reach statistical significance. Of note, none of the monotherapies (metformin only, sulfonylureas only, insulin only) were associated with a significant reduction of gynecological cancer incidence rates compared with non-users. Although the biological mechanism of how antidiabetic medications affect cancer risk is not clear, some evidence suggests that insulin signaling and lipid deregulation in patients with type 2 diabetes may enhance cancer development. Hence, a combination of antidiabetic medications that counter these mechanisms may contribute to the overall cancer risk reduction. Thus, it is possible that the protection is related more to improved glycemic control overall among these patients via multiple mechanisms. It is also possible that these patients who used multiple antidiabetic medications included patients with type 2 diabetes with a lower body size; cancer is postulated to be a secondary consequence of obesity.

Our results are consistent with a few prior studies of metformin. For example, some authors have disputed the concept of metformin monotherapy as an antineoplastic agent altogether. A similar study using pharmacy records of a large managed care organization also did not find an association between metformin and breast cancer, although it did not examine endometrial or ovarian cancer risk. It has been suggested that the reduced cancer rates seen among metformin users may be attributed to patients with type 2 diabetes using insulin or insulin secretagogues. In our study, we found that women with type 2 diabetes using metformin with insulin had a lower incidence for breast cancer, but the rates were not different from those for women who used metformin with other (non-insulin) antidiabetic medications.

Table 3 shows that metformin only users had generally similar high cancer rates as did the non-metformin combination users, while sulfonylureas users had the lowest rates. This may be related to the American Diabetes Association and the European Association for the Study of Diabetes; the recommended approach to management of hyperglycemia in patients with type 2 diabetes begins with lifestyle modification and low-dose metformin. From there, clinicians are encouraged to check blood glucose and HbA1c levels and titrate the metformin dosing, so as to minimize gastrointestinal side effects from the medication. If patients are not achieving target HbA1c levels, recommendations then include adding other medications from different drug classes, typically starting with sulfonylureas and then switching to other hypoglycemics based on tolerability and effectiveness. Thus, patients on a regimen which included metformin with sulfonylureas or other antidiabetic medications likely represent a subpopulation exposed to metformin for a longer duration and at the maximal metformin dosing. In contrast, single-agent metformin users may represent a population whose glucose management was maintained at lower doses of metformin, or were earlier in their treatment course. We addressed this potential confounding by adjusting for comorbidity status (using the Charlson score), the number of outpatient visits, and the HbA1c level as surrogates for diabetes severity. In addition, to minimize confounding by indication, we also conducted sensitivity analyses restricted to the women who were ever prescribed antidiabetic medications (table 3). Sulfonylureas only users generally had the lowest cancer rates (table 2). Our results are also consistent with the results of a recent meta-analysis that reviewed the relationship between metformin and sulfonylureas and their relationship to cancer risks. Our cohort demonstrated that while metformin users had some of the highest cancer rates, use of metformin with sulfonylureas mitigated that risk. Hence, since sulfonylureas are insulin secretagogues, the mechanism by which metformin lowers cancer risk is not simply by reducing circulating insulin.

As with any study, certain limitations must be considered. We were not able to adjust for some important covariates, including body mass index. Since body mass index was not available in the KPSC electronic health records until 2006, residual confounding might be possible. However, another large study of patients with diabetes in a managed care system determined that the inclusion of body mass index did not confound their results. Although we used time-dependent medication variables in the Cox model, this method did not fully statistically address the complicated issue of drug switching. Nonetheless, we were able to apportion person-time into several different antidiabetic drug combination categories, as well as count person-years of exposure starting from drug initiation, thereby reducing immortal time bias. A substantial percentage (34%) disenrolled from the health plan. Disenrolled patients were more likely to be younger at baseline, of minority backgrounds, and have less comorbidity (although their distributions of antidiabetic medications at baseline were similar to those patients whose end points were ascertained). Therefore, the generalizability of this study may be limited. Our study was also limited by an inability to distinguish between premenopausal and postmenopausal estrogen use, which has implications for endometrial and breast cancer risk. Again, we believe this limitation to be minimal as ERT is unlikely to be associated with a particular type of hypoglycemic prescribing within the cohort of women with diabetes. Also, given that carcinogenesis has a long latency, the effects of the antidiabetic drugs may not be observed months or years after that exposure at which point a patient might have been on additional or different diabetic medications. Therefore, exposure might have been misclassified for some individuals. However, in a breast cancer prevention trial of estrogen and progestin in the Women’s Health Initiative, Santen and colleagues estimated that nearly 94% of women who developed breast cancer during the 5-year follow-up study actually had occult tumor lesions at baseline.
Taking these two points together, antidiabetic drugs may act as promoters of carcinogenesis rather than initiators.

Aside from these drawbacks, this study has several key strengths. An important strength was the large size of our cohort; this population-based cohort study of patients with type 2 diabetes is larger than many found in European national databases. We were able to account for several confounders not available in other observational cohort studies. In addition, we were able to compare cancer incidence across various mutually exclusive antidiabetic drug use categories. Further, the study cohort is also unique in its racial/ethnic diversity. With nearly 50% minority women, this makes our findings more broadly applicable. Another important advantage was that the study was based on an integrated healthcare delivery system with comprehensive access to pharmacy utilization that modeled risks using time-dependent drug variables. Many of the prior observational studies were limited by self-reports of the cancer outcomes, covariates, lack of pharmacy data, or inadequate statistical analyses.

Given the insured study population, the results may not be generalizable to all settings; however, the characteristics of the KPSC membership are similar to the communities it serves in southern California. Future studies should consider examining the cancer risk according to the dose and timing of the antidiabetic medications, and if body mass index modifies this risk.

In summary, we observed a slightly lower breast cancer risk among women with type 2 diabetes who used a combination of antidiabetic medications with metformin compared with metformin only users; however, the results were not statistically significant. Overall, our results do not strongly support metformin monotherapy for cancer chemoprevention. Larger studies with a longer follow-up are needed to evaluate metformin’s potential effect on other gynecological cancers.

Contributors All authors contributed to the conception and design. RH, SEL, JS, and JC were responsible for data collection and assembly. All authors contributed to data analysis and interpretation, and manuscript preparation, and approved the final manuscript.

Funding This work was supported by Kaiser Permanente Southern California, Department of Research and Evaluation. Additional support came from NIH/NCI R01CA136743, ‘Antidepressants and Breast Cancer Pharmacopeidemiology’ (RH).

Competing interests None.

Ethics approval Kaiser Permanente Southern California IRB.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The authors welcome inquiries from external investigators for collaborations. Collaborations may require data use agreements with KPSC as authors are not free to release participants’ personal data under KPSC’s promise to safeguard confidentiality. Requests for collaboration must be submitted to the corresponding author. Before collaborations can be initiated, proposals require a review and approval by the study team and the KPSC contracts office. Additionally, funding may be required to support the future analyses conducted by KPSC staff. This purpose of the study committee is to: (A) ensure accurate reporting of KPSC data, (B) maintain the scientific integrity, and (C) safeguard the rights and confidentiality of the KPSC health plan members.

REFERENCES

1. Ciol NF, Ochs L, Springmann V, et al. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012;135:639–46.
2. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:337–44.
3. Evans JM, Donnelly LA, Emelie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304–5.
4. Michels KB, Solomon CG, Hu FB, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care 2003;26:1752–8.
5. Goodwin PJ, Pritchard KI, Ennis M, et al. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 2008;8:501–5.
6. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269–73.
7. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and reduces cell cycle arrest in vitro. J Cell Cycle 2009;8:909–15.
8. Chlebowski RT, McInteman A, Wacatawski-Wende J, et al. Diabetes, metformin and breast cancer in postmenopausal women. J Clin Oncol 2012;30:2844–52.
9. Suisse S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665–73.
10. Azoulay L, Dell’Aniello S, Gagnon B, et al. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011;20:513–8.
11. Yang YX, Hennessey S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004;127:1044–50.
12. Chung YW, Han DS, Park KH, et al. Insulin therapy and colorectal adenoma risk among patients with type 2 diabetes mellitus: a case-control study in Korea. Dis Col Rectum 2008;51:593–7.
13. Patel T, Hruby G, Badani K, et al. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 2010;76:1240–4.
14. Niraula S, Pond G, de Wit R, et al. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J 2013;7:E74–8.
15. Suh S, Kang M, Kim MY, et al. Korean type 2 diabetes patients have multiple adenomatous polyps compared to non-diabetic controls. J Korean Med Sci 2011;26:1196–200.
16. Bayraktar S, Hernandez-Aya LF, Lei X, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor negative breast cancer. Cancer 2012;118:1202–11.
17. Landman GW, Kleefstra N, van Halteren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetic patients. Diabetes Care 2013;36:1002–7.
18. Bodmer M, Meier C, Krahenvbuhl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304–8.
19. Lehman DM, Lorenzo C, Hernandez J, et al. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 2013;35:1002–7.
20. Murtola TJ, Tammiela TL, Lahtela J, et al. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol 2008;168:925–31.
21. Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482–8.
22. Donadon V, Balbi M, Ghersetti M, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009;15:2506–11.
23. Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009;46:279–84.
24. Currie CJ, Poole CD, Jenkins-Jones S, et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012;35:299–304.
25. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. *Diabetes Care* 2012;35:119–24.

26. Sadeghi N, Abbruzzese JL, Yeung SC, et al. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. *Clin Cancer Res* 2012;18:2905–12.

27. Garrett CR, Hassabo HM, Bhadkamkar NA, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. *Br J Cancer* 2012;106:1374–8.

28. Shaw J, Lamia KA, Vasquez D, et al. The Kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science* 2005;310:1642–6.

29. Ben-Sahra I, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. *Cancer Res* 2011;71:4366–72.

30. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. *Nat Rev Cancer* 2011;11:886–95.

31. Santen RJ, Song Y, Yue W, et al. Effects of menopausal hormonal therapy on occult breast tumors. *J Steroid Biochem Mol Biol* 2013;137:150–6.